Why the headlines overstate the cure
The review’s headline, “MMA cuts opioids”, sounds like a silver bullet, but the data only cover the first few days after surgery. In plain English: the drug packs help for a short window, then the benefit disappears. And the claim that they will solve the opioid crisis is simply premature.
What the review actually examined
The authors didn’t conduct a new trial. They sifted through dozens of existing studies and pulled out the most common multimodal analgesia (MMA) components used in three surgical groups:
- Orthopedic operations, NSAIDs or selective COX-2 inhibitors, nerve blocks, local ropivacaine infiltration, and acetaminophen.
- Breast surgery, the same drug mix plus PECS I/II and paravertebral blocks.
- Amputations, NSAIDs, round-the-clock acetaminophen, and a single gabapentin trial.
Their primary outcomes were pain scores (usually on a 0-10 scale) and opioid consumption measured in morphine-equivalent milligrams. No mortality, functional recovery, or quality-of-life metrics were systematically analyzed.
The numbers the headlines skip
| Finding | Plain-English meaning |
|---|---|
| 75% of surgical patients feel pain post-op | Pain is the rule, not the exception. |
| 86% of those rate it moderate-to-severe | Most patients are not just “a little sore.” |
| about 66% of knee/hip patients with ropivacaine infiltration need no extra morphine | Two-thirds avoid opioids, but the other third still may need them, and the study only looked at the first day or two. |
| Opioid-related deaths in the US rose 8-fold (1999-2016) | The crisis is real; any reduction in opioid use is welcome, but the review does not prove MMA will curb deaths. |
The short-term opioid drop is real, but when you ask “does it keep patients pain-free for weeks or months?” the answer is unknown, and the review stops at 30 days, leaving a huge gap in our understanding of long-term outcomes.
NSAIDs and COX-2 inhibitors: not a magic bullet
NSAIDs and selective COX-2 inhibitors repeatedly show lower pain scores and fewer opioids in spine and joint surgery. That sounds like a win, until you remember:
- Bleeding risk: Traditional NSAIDs can increase surgical bleeding, a complication the review glosses over.
- Kidney worries: Even short-term NSAID use can impair renal function, especially in older patients.
- Heart danger: COX-2 inhibitors spare the stomach but carry a cardiovascular warning that the article mentions only in passing.
So while the drugs help with pain, they also bring a different set of hazards that are not captured in the simple “opioid-use reduction” headline.
The safety myth: swapping one risk for another
The review paints gabapentinoids (gabapentin, pregabalin) as a neat adjunct for amputations and breast surgery. Yet the authors admit:
- Sedation and dizziness are common side effects, especially when combined with opioids.
- No solid data on how gabapentinoids interact with NSAIDs or COX-2 inhibitors.
In other words, the “multimodal” label can mask the fact that we are stacking drugs with overlapping side-effect profiles. The safety tables in the original studies are thin, and the review does not provide a consolidated risk assessment.
Beyond NSAIDs: the drugs this review skips
The toolkit is wider than these three surgical groups suggest. A separate MD Anderson review of perioperative opioid use rounds out the picture, and it is more honest about where the evidence is thin.
Take low-dose ketamine. Most people know it as an anesthetic or a club drug. But at infusion doses of 0.1 to 0.2 mg/kg per hour, a 2018 Cochrane review of 130 studies found it cut both opioid use and pain scores at 24 and 48 hours after surgery. The effect is clearest in bigger abdominal and orthopedic operations. It is not free of baggage. Sedation and dissociation are real. The data putting it in the mix, though, is not in doubt.
Then there is esmolol, a beta-blocker nobody thinks of as a painkiller. A 2018 meta-analysis of 23 randomized trials found it lowered opioid use both during and after surgery. Why a heart-rate drug does this is still argued over. It keeps showing up in the numbers anyway.
Intravenous lidocaine is the cautionary tale. It sounds promising, and some trials deliver. But a Cochrane review of 68 trials covering 4,525 patients came back inconclusive, with results that flatly conflict. That is the reminder worth keeping: “non-opioid adjunct” is not a synonym for “proven.” Some of these agents earn their spot. Others are still an open question.
The missing pieces, why optimism is premature
- Procedure-specific RCTs are scarce. Most meta-analyses pool heterogeneous surgeries, making it hard to know which cocktail works best for a given operation.
- Long-term pain is barely studied. Chronic post-surgical pain (lasting >= 3 months) is a major disability, but the review’s data stop at 30 days.
- Predictive tools are still a dream. The authors call for machine-learning models to tailor regimens, yet no such system exists in clinical practice.
- Adverse-event reporting is patchy. Few studies detail bleeding, renal, or cardiovascular events when NSAIDs are combined with other agents.
Until these gaps are filled, the claim that MMA will “solve the opioid crisis” is overly hopeful. It is a promising strategy, not a proven cure-all.
What you should do before your surgery
- Ask your surgeon or anesthesiologist which non-opioid options they plan to use.
- Know your medical history. If you have kidney disease, heart problems, or a bleeding disorder, NSAIDs or COX-2 inhibitors may be off-limits.
- Don’t expect a pain-free miracle. Even with MMA, many patients still report moderate-to-severe pain in the first days after surgery.
- Watch for side effects. Dizziness, stomach upset, or unusual bruising should be reported immediately.
- Consider a pain-management plan that includes non-pharmacologic strategies, ice, movement. And physical therapy, alongside any drug regimen.
Take charge of your recovery. A conversation with your care team can turn a vague “multimodal plan” into a concrete, personalized approach that balances pain relief with safety.
Sources:
- pmc.ncbi.nlm.nih.gov, “Multimodal Analgesia in the Perioperative Period of Major …” (https://pmc.ncbi.nlm.nih.gov/articles/PMC12463453/)
- sciencedirect.com, “Oral Multimodal Analgesia for Total Joint Arthroplasty” (https://www.sciencedirect.com/science/article/abs/pii/S0883540317304023)
- asra.com, “Multimodal Analgesia: Role of Non Opioid Analgesics” (https://asra.com/news-publications/asra-updates/blog-landing/legacy-b-blog-posts/2019/08/06/multimodal-analgesia-role-of-non-opioid-analgesics)
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.